Dr Know
The ‘Clinician of the Future 2023’ report suggests that healthcare professionals are preparing to embrace generative AI
Familiar foe
As winter looms, so too does a name that sends chills through our collective soul – COVID-19. The pantomime baddie we hoped we’d seen the back of.
In reality, COVID-19 does not represent the terrifying existential threat of 2020. It is now simply part of the ever-circulating family (and I use that term loosely) of viruses that enter and leave our systems at will.
The only major diference being that we all know the name of this one. It is still not widely appreciated. However, that the entire reason for COVID-19’s status as ‘just another virus’ is the work of the life sciences industry (shout out to Professor Sarah Gilbert!).
And it’s worth reiterating that the current status quo of relative COVID calm is not due to Boris Johnson or Matt Hancock or Harry & Meghan, or Bluey for that matter. It is squarely down to the unheralded lab crews of these fair isles.
Indeed, history may never truly recognise pharma as the defacto freedom fghter of the pandemic story, so I’m dropping it in here for posterity.
Navigating threats at light speed will continue to dictate the narrative, with technology, digital, AI and the life sciences taking a leading role. And thus, healthcare professionals – more specifcally doctors and nurses – will inevitably embrace ‘the future’, and collaborate with it.
Undoubtedly, from the tumult of industrial action and razzmatazz of an eradefning election, next year, the emergence of a match ft pharma/NHS union has never been more crucial.
The ‘Clinician of the Future 2023’ report suggests that healthcare professionals are preparing to embrace generative AI
Pierre Morgon is Executive Vice President of Portfolio Strategy and Supranational Affairs, as well as Managing Director Europe, at CanSino Biologics
How can pharma re-engage with primary care?
Overcoming time perception challenges in dementia through technology
The age-old challenge of diversity in clinical studies
From data to action – the healthcare revolution is gaining momentum
How pharma can utilise the power of Nordic real-world data
The difficulties of identifying and treating rare diseases